FATTY LIVER AND GUT MICROBIOTA: A NEW MULTI-DIMENSIONAL APPROACH FOR PERSONALIZED PREVENTIVE MEDICINE

  • F. Bonino | ferruccio.bonino@unipi.it Institute of Biostructure and Bioimaging, National Research Council, Naples; University of Pittsburgh Medical Center Institute for Health, Chianciano Terme, Siena, Italy.
  • M. Pane Biolab Research, Novara, Italy.
  • A. Amoruso Biolab Research, Novara, Italy.
  • M.R. Brunetto Hepatology Unit and Laboratory of Molecular Genetics and Pathology of Hepatitis Viruses, Reference Center of the Tuscany Region for Chronic Liver Disease and Cancer, University Hospital of Pisa and Internal Medicine, Department of Clinical and Experimental Medicine, University of Pisa, Italy.

Abstract

Cardiovascular, degenerative, hepato-digestive, metabolic and neoplastic diseases are major causes of death; all of them are beckoned years before by fatty liver that can quantify by non-invasive ultrasound methods. Such a measure is sensitive and reproducible and qualifies as mirror of general health to monitor the efficacy of preventive care in pre-symptomatic subjects. One major determinant of alimentary and general health is the gut microbiota that regulates hepatic gene expression, lipid metabolism and contributes to hepatic inflammation and obesity. The microbiota can be dynamically modified by probiotic/ prebiotic supplementation, however a direct gut microbiota profiling by stool metagenomics is limited by sampling error. The study of blood and/or saliva metabolites (metabolomics) and circulating antimicrobial antibodies provide an indirect microbiota profiling. Studies need to be performed to test whether variation of metabolomics and antimicrobial antibody levels correlate with the in vivo bacteria dynamics. The non-invasive measure of fatty liver in combination with of the gut microbiota characterization by metagenomics, metabolomics and anti-microbial enzyme immune assays will provide an innovative technological approach to stratify individuals with fatty liver for both prevention, outcome prediction and personalized treatment and to identify new aetiologies, diagnostic and prognostic biomarkers and therapeutic targets

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2019-09-05
Info
Issue
Section
Articles
Keywords:
Fatty Liver, Gut-Microbiota, Probiotics, Steatosis, ultrasound
Statistics
  • Abstract views: 538

  • PDF: 311
How to Cite
Bonino, F., Pane, M., Amoruso, A., & Brunetto, M. (2019). FATTY LIVER AND GUT MICROBIOTA: A NEW MULTI-DIMENSIONAL APPROACH FOR PERSONALIZED PREVENTIVE MEDICINE. Journal of the Siena Academy of Sciences, 10(1). https://doi.org/10.4081/jsas.2018.8531